An Ethanol Extract of


Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
18 May 2023
Historique:
received: 11 04 2023
revised: 09 05 2023
accepted: 16 05 2023
medline: 29 5 2023
pubmed: 27 5 2023
entrez: 27 5 2023
Statut: epublish

Résumé

In cell-based regenerative medicine, induced pluripotent stem cells (iPSCs) generated from reprogrammed adult somatic cells have emerged as a useful cell source due to the lack of ethical concerns and the low risk of immune rejection. To address the risk of teratoma formation, which is a safety issue in iPSC-based cell therapy, it is essential to selectively remove undifferentiated iPSCs remaining in the iPSC-derived differentiated cell product prior to in vivo transplantation. In this study, we explored whether an ethanol extract of coptidis rhizoma (ECR) exhibited anti-teratoma activity and identified the active components involved in the selective elimination of undifferentiated iPSCs. Transcriptome analysis of iPSCs confirmed that cell death-related pathways were significantly altered by ECR treatment. Our results demonstrate that ECR effectively induced apoptotic cell death and DNA damage in iPSCs, and that reactive oxygen species generation, mitochondrial damage, caspase activation, and p53 activation were involved in ECR-mediated iPSC death. However, in iPSC-derived differentiated cells (iPSC-Diff), reduced cell viability and the DNA damage response were not observed after ECR treatment. We co-cultured iPSCs and iPSC-Diff and found that ECR treatment selectively removed iPSCs, whereas iPSC-Diff remained intact. Prior to in ovo implantation, ECR treatment of a mixed cell culture of iPSCs and iPSC-Diff significantly suppressed iPSC-derived teratoma formation. Among the main components of the ECR, berberine and coptisine showed selective cytotoxicity to iPSCs but not to iPSC-Diff. Together, these results indicate the usefulness of ECRs in preparing safe and effective iPSC-based therapeutic cell products with no risk of teratoma formation.

Identifiants

pubmed: 37242247
pii: nu15102364
doi: 10.3390/nu15102364
pmc: PMC10221726
pii:
doi:

Substances chimiques

Drugs, Chinese Herbal 0
Ethanol 3K9958V90M

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Korea Institute of Oriental Medicine
ID : KSN2013240

Références

Phytomedicine. 2020 Apr;69:153198
pubmed: 32151917
Biomed Res Int. 2014;2014:798093
pubmed: 24818152
J Ethnopharmacol. 2015 Feb 23;161:69-81
pubmed: 25498346
Biochimie. 2019 Jul;162:176-184
pubmed: 31051209
Int J Mol Sci. 2021 Jul 28;22(15):
pubmed: 34360840
Oncogene. 2019 Mar;38(10):1597-1610
pubmed: 30348990
Cell Stem Cell. 2015 Jul 2;17(1):11-22
pubmed: 26140604
Nutrients. 2020 Mar 09;12(3):
pubmed: 32182802
BMC Cancer. 2010 Jan 05;10:4
pubmed: 20051134
Cell Chem Biol. 2017 Jun 22;24(6):685-694.e4
pubmed: 28529132
Int J Med Sci. 2018 Jan 1;15(1):36-45
pubmed: 29333086
BMC Biol. 2015 Oct 29;13:89
pubmed: 26515107
Front Pharmacol. 2022 Jan 03;12:775084
pubmed: 35046810
Cell Mol Life Sci. 2017 Jul;74(14):2601-2611
pubmed: 28246701
Bioinformatics. 2009 Apr 15;25(8):1091-3
pubmed: 19237447
Cancer Lett. 2000 Jan 1;148(1):19-25
pubmed: 10680588
Chin Med. 2018 Mar 07;13:13
pubmed: 29541156
Phytomedicine. 2022 Jul 20;102:154144
pubmed: 35537368
Front Cell Dev Biol. 2015 Feb 02;3:2
pubmed: 25699255
Sci Rep. 2017 Feb 06;7:38524
pubmed: 28165459
Molecules. 2022 Jul 15;27(14):
pubmed: 35889396
Curr Med Sci. 2020 Apr;40(2):257-264
pubmed: 32337687
PLoS One. 2013 Nov 29;8(11):e79541
pubmed: 24312182
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nat Rev Drug Discov. 2015 Oct;14(10):681-92
pubmed: 26391880
Bio Protoc. 2019 Jan 5;9(1):
pubmed: 30687773
J Biol Chem. 2012 Nov 9;287(46):38590-9
pubmed: 23012366
Metabolism. 2011 Feb;60(2):298-305
pubmed: 20304443
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Eur J Pharmacol. 2019 Sep 15;859:172523
pubmed: 31279667
Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):E3281-90
pubmed: 23918355
Cancer Manag Res. 2020 Jan 30;12:695-702
pubmed: 32099466
Cell. 2007 Nov 30;131(5):861-72
pubmed: 18035408
Regen Med. 2009 Sep;4(5):759-69
pubmed: 19761400
Molecules. 2021 Dec 06;26(23):
pubmed: 34885971
Pharm Biol. 2019 Dec;57(1):193-225
pubmed: 30963783
Int J Mol Sci. 2021 Apr 30;22(9):
pubmed: 33946527
Int J Mol Sci. 2020 May 05;21(9):
pubmed: 32380745

Auteurs

Aeyung Kim (A)

Korean Medicine (KM) Application Center, Korea Institute of Oriental Medicine, Daegu 41062, Republic of Korea.

Su-Jin Baek (SJ)

KM Data Division, Korea Institute of Oriental Medicine, Daejeon 34054, Republic of Korea.

Sarah Shin (S)

KM Science Research Division, Korea Institute of Oriental Medicine, Daejeon 34054, Republic of Korea.

Seo-Young Lee (SY)

KM Science Research Division, Korea Institute of Oriental Medicine, Daejeon 34054, Republic of Korea.

Sun-Ku Chung (SK)

KM Science Research Division, Korea Institute of Oriental Medicine, Daejeon 34054, Republic of Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH